{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:04:15Z","timestamp":1793329455716,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00270-021-03050-6","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T13:03:18Z","timestamp":1641301398000},"page":"298-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-Effectiveness of Urea Excipient-Based Drug-Coated Balloons for Chronic Limb-Threatening Ischemia from Femoropopliteal Disease in the Netherlands and Germany"],"prefix":"10.1007","volume":"45","author":[{"given":"Jan B.","family":"Pietzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle R.","family":"Iken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris P. S.","family":"van Wijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Holewijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel M. P. J.","family":"Reijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"issue":"7","key":"3050_CR1","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","volume":"36","author":"AE Attema","year":"2018","unstructured":"Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. Pharmacoeconomics. 2018;36(7):745\u201358.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"3050_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/1526602817710770","volume":"24","author":"Y Bausback","year":"2017","unstructured":"Bausback Y, Willfort-Ehringer A, Sievert H, et al. Six-month results from the initial randomized study of the ranger paclitaxel-coated balloon in the femoropopliteal segment. J Endovasc Ther. 2017;24(4):459\u201367.","journal-title":"J Endovasc Ther"},{"key":"3050_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.avsg.2019.07.004","volume":"63","author":"RB Biagioni","year":"2020","unstructured":"Biagioni RB, Nasser F, Matielo MF, et al. Comparison of bypass and endovascular intervention for popliteal occlusion with the involvement of trifurcation for critical limb ischemia. Ann Vasc Surg. 2020;63:218\u201326.","journal-title":"Ann Vasc Surg"},{"issue":"8","key":"3050_CR4","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.avsg.2013.01.010","volume":"27","author":"J Bosma","year":"2013","unstructured":"Bosma J, Vahl A, Wisselink W. Systematic review on health-related quality of life after revascularization and primary amputation in patients with critical limb ischemia. Ann Vasc Surg. 2013;27(8):1105\u201314.","journal-title":"Ann Vasc Surg"},{"issue":"7","key":"3050_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3111\/13696998.2016.1154567","volume":"19","author":"D Bruhn","year":"2016","unstructured":"Bruhn D, Martin AA, Tavares R, Hunt B, Pollock RF. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. J Med Econ. 2016;19(7):672\u201383.","journal-title":"J Med Econ"},{"issue":"2","key":"3050_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/j.tvir.2016.04.001","volume":"19","author":"A Dua","year":"2016","unstructured":"Dua A, Lee CJ. Epidemiology of Peripheral Arterial Disease and critical limb ischemia. Tech Vasc Interv Radiol. 2016;19(2):91\u20135.","journal-title":"Tech Vasc Interv Radiol"},{"issue":"2","key":"3050_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jvs.2018.05.255","volume":"69","author":"A Farber","year":"2019","unstructured":"Farber A, Rosenfield K, Siami FS, Strong M, Menard M. The BEST-CLI trial is nearing the finish line and promises to be worth the wait. J Vasc Surg. 2019;69(2):470\u201381.","journal-title":"J Vasc Surg"},{"issue":"5","key":"3050_CR8","first-page":"365","volume":"37","author":"OS Goksel","year":"2019","unstructured":"Goksel OS, Karpuzo\u011flu E, I\u015fsever H, \u00c7inar B. Midterm results with drug-coated balloons for SFA lesions in patients with CLI: comparison with conventional bypass surgery. Int Angiol. 2018;37(5):365\u20139.","journal-title":"Int Angiol"},{"key":"3050_CR9","unstructured":"InEK (2020) Fallpauschalen-Katalog 2020 (German-Diagnosis Related Groups-System). Institut f\u00fcr das Entgeltsystem im Krankenhaus (InEK GmbH), https:\/\/www.g-drg.de\/aG-DRG-System_2020\/Fallpauschalen-Katalog\/Fallpauschalen-Katalog_2020."},{"issue":"18","key":"3050_CR10","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.jcin.2016.06.055","volume":"9","author":"X Jia","year":"2016","unstructured":"Jia X, Zhang J, Zhuang B, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt I trial. JACC Cardiovasc Interv. 2016;9(18):1941\u20139.","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"3050_CR11","doi-asserted-by":"publisher","first-page":"e011245","DOI":"10.1136\/bmjopen-2016-011245","volume":"6","author":"K Katsanos","year":"2016","unstructured":"Katsanos K, Geisler BP, Garner AM, Zayed H, Cleveland T, Pietzsch JB. Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK. BMJ Open. 2016;6(5):e011245.","journal-title":"BMJ Open"},{"issue":"2","key":"3050_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/eurheartj\/ehq406","volume":"32","author":"MB Leon","year":"2011","unstructured":"Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the valve academic research consortium. Eur Heart J. 2011;32(2):205\u201317.","journal-title":"Eur Heart J"},{"issue":"2","key":"3050_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2471\/BLT.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118\u201324.","journal-title":"Bull World Health Organ"},{"issue":"2","key":"3050_CR14","first-page":"130","volume":"34","author":"FC Meng","year":"2018","unstructured":"Meng FC, Chen PL, Lee CY, Shih CC, Chen IM. Real-world comparison of drug-eluting and bare-metal stents in superficial femoral artery occlusive disease with trans-atlantic intersociety consensus B lesions: a 2-year. Single-Inst Study Acta Cardiol Sin. 2018;34(2):130\u20136.","journal-title":"Single-Inst Study Acta Cardiol Sin"},{"key":"3050_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.avsg.2019.05.013","volume":"62","author":"J Phair","year":"2020","unstructured":"Phair J, Carnevale M, Lipsitz EC, Shariff S, Scher L, Garg K. Amputation-free survival in patients with critical limb ischemia treated with paclitaxel-eluting stents and paclitaxel-coated balloons. Ann Vasc Surg. 2020;62:8\u201314.","journal-title":"Ann Vasc Surg"},{"issue":"4","key":"3050_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ccd.25536","volume":"84","author":"JB Pietzsch","year":"2014","unstructured":"Pietzsch JB, Geisler BP, Garner AM, Zeller T, Jaff MR. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany. Catheter Cardiovasc Interv. 2014;84(4):546\u201354.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"2","key":"3050_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejvs.2017.04.020","volume":"54","author":"MA Popplewell","year":"2017","unstructured":"Popplewell MA, Davies HOB, Narayanswami J, et al. A comparison of outcomes in patients with infrapopliteal disease randomised to vein bypass or plain balloon angioplasty in the bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial. Eur J Vasc Endovasc Surg. 2017;54(2):195\u2013201.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"3","key":"3050_CR18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/1526602819839044","volume":"26","author":"M Reijnen","year":"2019","unstructured":"Reijnen M, van Wijck I, Zeller T, et al. Outcomes after drug-coated balloon treatment of femoropopliteal lesions in patients with critical limb ischemia: a post hoc analysis from the IN.PACT global study. J Endovasc Ther. 2019;26(3):305\u201315.","journal-title":"J Endovasc Ther"},{"issue":"22","key":"3050_CR19","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1016\/j.jcin.2016.08.036","volume":"9","author":"AC Salisbury","year":"2016","unstructured":"Salisbury AC, Li H, Vilain KR, et al. Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: results from the IN.PACT SFA II trial. JACC Cardiovasc Interv. 2016;9(22):2343\u201352.","journal-title":"JACC Cardiovasc Interv"},{"key":"3050_CR20","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1016\/j.ejvs.2019.06.1132","volume":"58","author":"\u00c1 Santos","year":"2019","unstructured":"Santos \u00c1, Valdivia A, Alguacil S, Sanus E, Guaita J, Z\u00fa\u00f1iga C. One year results in the endovascular treatment of the femoro-popliteal segment with the Tigris\u00ae stent in patients with critical limb ischemia. Eur J Vasc Endovasc Surg. 2019;58:e466.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"3","key":"3050_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/1526602816644592","volume":"23","author":"D Scheinert","year":"2016","unstructured":"Scheinert D, Schmidt A, Zeller T, et al. German center subanalysis of the LEVANT 2 global randomized study of the lutonix drug-coated balloon in the treatment of femoropopliteal occlusive disease. J Endovasc Ther. 2016;23(3):409\u201316.","journal-title":"J Endovasc Ther"},{"issue":"5","key":"3050_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/CIRCULATIONAHA.114.011004","volume":"131","author":"G Tepe","year":"2015","unstructured":"Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the INPACT SFA randomized trial. Circulation. 2015;131(5):495\u2013502.","journal-title":"Circulation"},{"issue":"3","key":"3050_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/1358863X12440141","volume":"17","author":"TM Todoran","year":"2012","unstructured":"Todoran TM, Connors G, Engelson BA, Sobieszczyk PS, Eisenhauer AC, Kinlay S. Femoral artery percutaneous revascularization for patients with critical limb ischemia: outcomes compared to patients with claudication over 2.5 years. Vasc Med. 2012;17(3):138\u201344.","journal-title":"Vasc Med"},{"issue":"3","key":"3050_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s00270-015-1175-3","volume":"39","author":"A Torres-Blanco","year":"2016","unstructured":"Torres-Blanco A, Edo-Fleta G, Gomez-Palones F, Molina-Nacher V, Ortiz-Monzon E. Mid-term outcomes of endovascular treatment for TASC-II D femoropopliteal occlusive disease with critical limb ischemia. Cardiovasc Intervent Radiol. 2016;39(3):344\u201352.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3050_CR25","unstructured":"Nederlandse Zorgautoriteit. dbc-informatiesysteem (DIS); https:\/\/www.opendisdata.nl\/dis\/over, 2020."}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-021-03050-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-021-03050-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-021-03050-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T11:05:22Z","timestamp":1647255922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-021-03050-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3050"],"URL":"https:\/\/doi.org\/10.1007\/s00270-021-03050-6","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"16 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jan B. Pietzsch, Ph.D.: Dr. Pietzsch is the president, CEO, and a\u00a0shareholder of Wing Tech Inc., an independent research firm conducting health economic analyses. Wing Tech Inc. received consulting fees from Medtronic, Inc. to conduct the analyses underlying this study. Benjamin P. Geisler, M.D., M.P.H.: Dr. Geisler is a senior consultant for Wing Tech Inc., an independent research firm conducting health economic analyses. Wing Tech Inc. received consulting fees from Medtronic, Inc. to conduct the analyses underlying this study. Annabelle R. Iken, M.Sc.: Mrs. Iken is a research associate for Wing Tech Inc., an independent research firm conducting health economic analyses. Wing Tech Inc. received consulting fees from Medtronic, Inc. to conduct the analyses underlying this study. Iris van Wijck, BSc: No conflict of interest. Suzanne Holewijn, MSc, PhD: No conflict of interest. Michel M. P. J. Reijnen, MD, PhD: Dr. Reijnen received consulting fees and research funding from Medtronic, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}